Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

1. TRUST trial evaluated primary vs interval cytoreductive surgery. 2. Improved progression-free survival noted, yet overall survival not statistically significant. 3. 796 patients were enrolled with advanced ovarian cancer. 4. Significant benefits observed in patients with FIGO stage III disease. 5. Low surgical morbidity rates recorded in both treatment arms. 6. Study emphasizes importance of surgical quality assurance. 7. Results prompt reevaluation of surgical treatment strategies.